Loading...
  • vascular
  • Diabetic angiopathy is a generalized vascular lesion that spreads to both small vessels and vessels of medium and large caliber. (synthroidnews.net)
  • Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? (biomedsearch.com)
  • Prevention or restoration of these changes via blockade of aldosterone action in the vascular wall with MR antagonists (i.e., spironolactone, eplerenone) may therefore account for the clinical benefit of these compounds in obese and diabetic patients with cardiovascular disease. (biomedsearch.com)
  • This review will highlight recent evidence supporting the hypothesis that aldosterone and MR signaling represent an ideal candidate pathway linking early promoters of diabetes, especially overnutrition and obesity, to vascular insulin resistance, dysfunction, and disease. (biomedsearch.com)
  • In addition to well-established risks among diabetic subjects for vascular diseases, renal disease, blindness, and amputations ( 1 , 2 ), diabetes also is associated with a poorer outcome from several acute medical conditions, including myocardial infarction ( 3 ), possibly stroke ( 4 ), and certain severe infections ( 5 ). (diabetesjournals.org)
  • In addition, the study will evaluate whether new drugs to treat diabetic retinopathy will be able to reverse these vascular changes. (clinicaltrials.gov)
  • To test this hypothesis we will determine (1) how blood vessels remodel and whether vascular density truly decreases during diabetic retinopathy and (2) how the anti-angiogenic steroid triamcinolone acetonide affects vascular density and pattern during human diabetic retinopathy and in our experimental model, the avian CAM model. (clinicaltrials.gov)
  • In addition, a control group of 20 normal subjects will be recruited from the same clinical practice that do not have diabetes and no evidence of any vascular disease, for a total of 100 patients in the clinical trial. (clinicaltrials.gov)
  • Insulin
  • New generation diabetes management: glucose sensor augmented insulin pump therapy. (yale.edu)
  • The early pharmacodynamic and pharmacokinetic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. (yale.edu)
  • Patients with diabetes and/or the metabolic syndrome have a significantly increased risk of heart attack and stroke compared with people with normal insulin sensitivity. (biomedsearch.com)
  • Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. (clinicaltrials.gov)
  • Type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin treatment within 1 year of diagnosis of diabetes are included. (clinicaltrials.gov)
  • Two randomized trials were carried out in the DRVS among patients ages 18 to 70 years who had either insulin-dependent or non-insulin-dependent diabetes. (clinicaltrials.gov)
  • To date, EGRIFTA® has not been studied for longer than 1 year in human subjects, nor has EGRIFTA® been studied in Type 2 diabetic HIV-infected subjects who are receiving oral hypoglycemic agents, GLP-1 analogues, or insulin. (clinicaltrials.gov)
  • Thiazolidinediones (TZDs) are insulin sensitizers that decrease plasma glucose in type 2 diabetic patients. (clinicaltrials.gov)
  • treatment
  • From pumps to prevention: recent advances in the treatment of type 1 diabetes Jennifer Sherr, MD, Eda Cengiz, MD, and William V. Tamborlane, MD Drug Discov Today. (yale.edu)
  • Recent advances in the treatment of type 1 diabetes in children Recent advances in the treatment of type 1 diabetes in children. (yale.edu)
  • Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale [ Time Frame: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year. (clinicaltrials.gov)